title: Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy.
abstract: Inflammatory breast cancer (IBC) is a rare but aggressive form of breast cancer with a 5-year survival limited to approximately 40%. Diagnosis, based on clinical and/or pathological criteria, may be difficult. Optimal systemic neoadjuvant therapy and accurate predictors of pathological response have yet to be defined for increasing response rate and survival. Using DNA microarrrays containing approximately 8,000 genes, we profiled breast cancer samples from 81 patients, including 37 with IBC and 44 with noninflammatory breast cancer (NIBC). Global unsupervised hierarchical clustering was able to some extent to distinguish IBC and NIBC cases and revealed subclasses of IBC. Supervised analysis identified a 109-gene set the expression of which discriminated IBC from NIBC samples. This molecular signature was validated in an independent series of 26 samples, with an overall performance accuracy of 85%. Discriminator genes were associated with various cellular processes possibly related to the aggressiveness of IBC, including signal transduction, cell motility, adhesion, and angiogenesis. A similar approach, with leave-one-out cross-validation, identified an 85-gene set that divided IBC patients with significantly different pathological complete response rate (70% in one group and 0% in the other group). These results show the potential of gene expression profiling to contribute to a better understanding of IBC, and to provide new diagnostic and predictive factors for IBC, as well as for potential therapeutic targets.
authors.affiliation: Département d'Oncologie Moléculaire, Institut Paoli-Calmettes and UMR599 Institut National de la Santé et de la Recherche Médicale, IFR137, Marseille, France.
authors.forename: François
authors.initials: F
authors.lastname: Bertucci
authors.forename: Pascal
authors.initials: P
authors.lastname: Finetti
authors.forename: Jacques
authors.initials: J
authors.lastname: Rougemont
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Charafe-Jauffret
authors.forename: Valéry
authors.initials: V
authors.lastname: Nasser
authors.forename: Béatrice
authors.initials: B
authors.lastname: Loriod
authors.forename: Jacques
authors.initials: J
authors.lastname: Camerlo
authors.forename: Rebecca
authors.initials: R
authors.lastname: Tagett
authors.forename: Carole
authors.initials: C
authors.lastname: Tarpin
authors.forename: Gilles
authors.initials: G
authors.lastname: Houvenaeghel
authors.forename: Catherine
authors.initials: C
authors.lastname: Nguyen
authors.forename: Dominique
authors.initials: D
authors.lastname: Maraninchi
authors.forename: Jocelyne
authors.initials: J
authors.lastname: Jacquemier
authors.forename: Rémi
authors.initials: R
authors.lastname: Houlgatte
authors.forename: Daniel
authors.initials: D
authors.lastname: Birnbaum
authors.forename: Patrice
authors.initials: P
authors.lastname: Viens
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D008875:Middle Aged; D005810:Multigene Family; D020411:Oligonucleotide Array Sequence Analysis; D011237:Predictive Value of Tests; D012334:RNA, Neoplasm / Q000096:biosynthesis / Q000235:genetics; D014158:Transcription, Genetic; D016896:Treatment Outcome
chemical_list: D012334:RNA, Neoplasm